Empagliflozin as adjunct to insulin in Japanese participants with type 1 diabetes: Results of a 4‐week, double‐blind, randomized, placebo‐controlled phase 2 trial

AIMS: This phase 2, double‐blind, randomized, placebo‐controlled trial (http://clinicaltrials.gov NCT02702011) with 4 sites in Japan investigated the pharmacodynamics (PD), pharmacokinetics (PK) and safety profile of empagliflozin in Japanese participants with type 1 diabetes mellitus (T1DM) as adju...

Descripción completa

Detalles Bibliográficos
Autores principales: Shimada, Akira, Hanafusa, Toshiaki, Yasui, Atsutaka, Lee, Ganghyuck, Taneda, Yusuke, Sarashina, Akiko, Shiki, Kosuke, George, Jyothis, Soleymanlou, Nima, Marquard, Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6099358/
https://www.ncbi.nlm.nih.gov/pubmed/29766633
http://dx.doi.org/10.1111/dom.13351

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6099358/
https://www.ncbi.nlm.nih.gov/pubmed/29766633
http://dx.doi.org/10.1111/dom.13351

Ejemplares similares